Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin

Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin

We conducted a prospective study to determine the effect of intravenous low-dose iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin (rHuEPO). Sixteen hemodialysis patients (8 males and 8 females; mean age 63.1+/-9.8 years) on maintenance rHuEPO therapy...

Full description

Saved in:
Bibliographic Details
Published in:Renal failure Vol. 24; no. 2; p. 245
Main Authors: Harmankaya, Ozlem, Eran, Akif
Format: Journal Article
Language:English
Published: England 01-01-2002
Subjects:
Aged
Anemia - blood
Anemia - etiology
Anemia - prevention & control
Dose-Response Relationship, Drug
Erythropoietin - administration & dosage
Erythropoietin - blood
Erythropoietin - therapeutic use
Female
Ferric Compounds - administration & dosage
Ferric Compounds - blood
Ferric Compounds - therapeutic use
Ferric Oxide, Saccharated
Glucaric Acid
Hematinics - administration & dosage
Hematinics - blood
Hematinics - therapeutic use
Humans
Infusions, Intravenous
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - therapy
Male
Middle Aged
Prospective Studies
Recombinant Proteins
Renal Dialysis - adverse effects
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a prospective study to determine the effect of intravenous low-dose iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin (rHuEPO). Sixteen hemodialysis patients (8 males and 8 females; mean age 63.1+/-9.8 years) on maintenance rHuEPO therapy were included in the study. Patients with <100 ng/ml of ferritin received 50 mg iron during every hemodialysis session. Patients with 100-200 ng/ml of ferritin were given 50 mg iron fortnightly. Iron was not supplemented in patients with ferritin levels >200 ng/ml. Mean hematocrit, serum iron levels and transferrin saturations were significantly higher at 6 and 12 months. There was a significant reduction in weekly rHuEPO doses between the start and the 6th and 12th months. Our study shows intravenous iron administration of 100 mg/month may be sufficient to achieve a satisfactory iron status in dialysis patients on maintenance rHuEPO therapy.
ISSN:0886-022X
DOI:10.1081/JDI-120004103